The Medical Briefing  Nephrology

Povetacicept in IgA nephropathy, subphenotypes of septic AKI, calciphylaxis and vitamin K, complicated urinary tract infections

November 2026 edition (2/4)

The essentials in four articles

■ Glomerular disease
In the RAINIER trial, monthly povetacicept reduced proteinuria by 52% at 36 weeks, with a marked fall in Gd-IgA1; a benefit on eGFR remains to be demonstrated.

■ AKI and critical care
Plasma proteomic profiling of 1,099 patients identifies two subphenotypes of sepsis-associated AKI, including a hyperinflammatory profile with a worse prognosis.

■ CKD and dialysis
Calciphylaxis: vitamin K is a promising pathophysiological target, but supplementation cannot yet be recommended; the BEAT-Calci trial is under way.

■ Clinical nephrology
The IDSA 2025 guidelines support 7-day courses, or even 5 to 7 days with fluoroquinolones, in complicated urinary tract infections with a favorable clinical course.